Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 5;6(2):22.
doi: 10.3390/reports6020022.

The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report

Affiliations
Case Reports

The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report

Marina Antonini et al. Reports (MDPI). .

Abstract

Glioblastoma is the most aggressive malignant tumor overall and remains an incurable neoplasm with a median survival of 15 months. Since 2005, the gold standard treatment for glioblastoma has remained unchanged, and it is a common goal of the scientific community to work towards a better prognosis and improved survival for glioblastoma patients. Herein, we report a case of glioblastoma multiforme in a patient with a poor prognosis who, following partial removal of the neoplasm, refused conventional therapy consisting of a combination of radiotherapy and temozolomide-based chemotherapy due to personal serious side effects. The patient started an unconventional therapeutic path by alternating periods of oxygen-ozone therapy with concomitant administration of legal medical cannabis products (Bedrocan and Bedrolite) and melatonin. This approach resulted in a complete and durable remission of the disease and long survival. Indeed, the patient is still alive. The exceptional result obtained here encourages us to share and carefully investigate this unconventional treatment as a possible future direction in the management of glioblastoma.

Keywords: cannabinoids; chemotherapy; glioblastoma; melatonin; oxygen–ozone therapy; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Computerized tomography (CT) scan with contrast medium performed at initial diagnosis (21 August 2016) showed, in the left fronto-parietal area, two voluminous formations and inhomogeneous contiguous focalities of 52 × 41 mm and 40 × 20 mm, respectively, characterized by irregular peripheral impregnation and contextual necrotic-colliquative areas, with surrounding perilesional digitiform hypodensity, compression of the lateral ventricle, and contralateral shift of the midline structures (1 cm).
Figure 2
Figure 2
12 October 2016, instrumental examination after partial removal of left frontal multicentric neoplasm. The CT scan images with contrast medium showed an apparently reduced liqueur-like collection with associated wall impregnation. Posterior to the surgical cavity, there is an approximately 2 cm hyperdense solid nodule characterized by contrast-enhancing impregnation.
Figure 3
Figure 3
(a,c) 12 October 2016, CT scan image with contrast medium. Posterior to the surgical cavity, an approximately 2 cm hyperdense solid nodule is present (b) 9 February 2017, MRI T1 sequence with contrast medium. After the first cycle of O2O3 therapy, the 2 cm residual tumor mass that was present 3 months before was no longer visible (d) 9 February 2017, MRI image sequence in Fluid-attenuated inversion recovery (FLAIR).
Figure 4
Figure 4
11 October 2022, instrumental examination, stable negative picture. (a,b,f) MRI images, T1 sequence with contrast medium. (ce) MRI images, sequence in FLAIR. The morphological picture remained stationary—the T2 hyperintensity surrounding the known left frontal malacic cavity extended to the knee and right root of the corpus callosum and in the left semioval center and was without mass effect and not modified in the contrastographic phases. Non-focality of new onset at the remaining levels. In the spongiosa of the left frontal bone in the median region and on the profile of the operculum, there are two areas of altered signal with contrastographic impregnation, both of which are stationary. The median structures are on an axis. The ventricular cavities and subarachnoid spaces are overlapping in size and morphology.
Figure 5
Figure 5
(a) 21 August 2016, CT image with contrast medium before surgery. (b) 12 October 2016, CT image with contrast medium after partial removal of left frontal multicentric neoplasm. (c) 9 February 2017, MRI image, T1 sequence with contrast medium after the first cycle of oxygen-ozone therapy. (d) 12 July 2021, MRI image sequence in FLAIR. (e) 24 February 2022, MRI image sequence in FLAIR. (f) 11 October 2022, MRI image sequence in FLAIR. Following a total of 5 years after the partial resection surgery, the morphological picture remained stable, and the patient was considered cured.

Similar articles

References

    1. Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Rei-fenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
    1. Ostrom Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:iv1–iv96. doi: 10.1093/neuonc/noaa200. - DOI - PMC - PubMed
    1. Koshy M., Villano J.L., Dolecek T.A., Howard A., Mahmood U., Chmura S.J., Weichselbaum R.R., McCarthy B.J. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neurooncol. 2012;107:207–212. doi: 10.1007/s11060-011-0738-7. - DOI - PMC - PubMed
    1. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Nwagwu C.D., Adamson D.C. Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma? Expert Opin. Pharmacother. 2021;22:1983–1994. doi: 10.1080/14656566.2021.1950139. - DOI - PubMed

Publication types

LinkOut - more resources